Skip to main
OCGN

Ocugen, Inc. (OCGN) Stock Forecast & Price Target

Ocugen, Inc. (OCGN) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocugen Inc. is engaged in the development of innovative gene and cell therapies, with a focus on addressing unmet medical needs in retinal diseases through its modifier gene therapy platform. The potential upside for the company's stock is bolstered by the promising efficacy and safety profile of OCU400 in its ongoing phase I/II studies, as well as attractive collaboration opportunities and the potential for mergers and acquisitions. Overall, the strength of Ocugen's pipeline and strategic initiatives positions the company favorably within the biotechnology sector, contributing to a positive outlook on its stock.

Bears say

Ocugen Inc.'s recent struggles to secure necessary investments have been attributed to poor market conditions and the pressing timeline for Nasdaq compliance, underscoring concerns related to its financial stability. Additionally, the company's pipeline includes novel therapies for retinal diseases, yet emerging treatment methods could potentially render Ocugen's existing therapies non-competitive or obsolete, further complicating its market position. These factors suggest a challenging future for Ocugen, characterized by uncertainty in both funding and competitive standing within the biotech sector.

Ocugen, Inc. (OCGN) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocugen, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocugen, Inc. (OCGN) Forecast

Analysts have given Ocugen, Inc. (OCGN) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Ocugen, Inc. (OCGN) has a Strong Buy consensus rating as of Jan 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocugen, Inc. (OCGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.